65 Equity Partners
65 Equity Partners provides bespoke capital solutions, typically investing US$50-150 million in established family-owned and entrepreneur-led middle-market businesses. It generally invests as a supportive minority shareholder but may consider co-controlling stakes.
What stands out about 65 Equity Partners
65 Equity Partners focuses on established, well-managed family-owned and entrepreneur-led businesses with clear growth strategies in consumer, industrials, business services, healthcare and technology. Its stated investment range is typically US$50-150 million, with investment activity across Southeast Asia, Europe and the United States.[1][2][3][5][8][9]
What does 65 Equity Partners invest in?
65 Equity Partners is a global investment firm that partners with founders and invests in family-owned and entrepreneur-led businesses in Southeast Asia, Europe and the United States. Temasek identifies it as an independently managed wholly-owned investment platform.
The firm states that it provides bespoke capital solutions, including growth funding, M&A financing, shareholder reorganisations and balance-sheet optimisation. It typically invests US$50-150 million and generally describes itself as a supportive minority shareholder, while also considering co-controlling stakes.[1][2][3]
65 Equity Partners operates through Local Enterprise Fund, Anchor Fund and International Fund strategies. The Local Enterprise Fund supports Singapore-based enterprises with business expansion and regionalisation. The Anchor Fund invests in high-growth Southeast Asian companies ahead of an eventual listing in Singapore, either on a standalone basis or alongside a listing in another market.
The International Fund partners with established founder-led and family-owned companies in Europe and the United States. The firm describes itself as a committed, long-term trusted partner with the ability to commit capital for up to 7 years.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
Published criteria: 65 Equity Partners states that it has US$4.2 billion in funds under management and typically invests US$50-150 million in well-managed family-owned and entrepreneur-led businesses with clear growth strategies. Temasek's launch announcement stated that the platform would principally invest in established companies with regional or global aspirations and market values between approximately US$1 billion and US$5 billion.[1][2]
What should a business owner evaluate before considering a transaction with 65 Equity Partners?
For an owner evaluating a sale or minority recapitalisation, the stated characteristics to assess include the business’s ownership profile, middle-market positioning, growth strategy, regionalisation or M&A plans, sector and geography, and the proposed investment amount. The firm states that it generally invests as a supportive minority shareholder, may consider co-controlling stakes and can provide straight or structured equity.
Owners should clarify the legal entity and fund making the investment, the proposed security and control position, governance rights, valuation methodology, available capital for follow-on acquisitions or international expansion, ownership duration, exit approach and transaction-level financing terms.[1][3][5][8][9]
What valuation range, preferred terms, governance rights and liquidity provisions would apply
What companies does 65 Equity Partners target?
The firm typically invests US$50-150 million in well-managed family-owned and entrepreneur-led businesses with clear growth strategies. Temasek’s launch announcement stated that 65 Equity Partners would principally invest in established companies with regional or global aspirations and market values between approximately US$1 billion and US$5 billion.[2][3]
The stated sector focus covers consumer, industrials, business services, healthcare and technology. The firm describes its target companies as established industry-leading middle-market companies.[3]
65 Equity Partners states that it invests in Southeast Asia, Europe and the United States. Its listed offices are in Singapore, London, Paris, San Francisco, New York and Milan.[3]
65 Equity Partners operates through three investment strategies: Local Enterprise Fund, Anchor Fund and International Fund. Public portfolio examples include the establishment or support of operating platforms and an acquisition involving TDConnex.[3][6]
Official portfolio materials identify DayOne as a Singapore technology investment, and describe businesses and platforms including Hi-P, a Singapore-headquartered advanced manufacturer; TDConnex, a precision-manufacturing business; and Tamarind Health, a healthcare group established with its founding doctors.
Other cited portfolio examples include the healthcare businesses HAS Healthcare Advanced Synthesis and Cerbios-Pharma, as well as Theop, for which 65 Equity Partners announced a partnership investment alongside the founders and Florac.[4][5][6][7]
On July 9, 2026, 65 Equity Partners announced a partnership investment in Theop alongside the founders and Florac. The official portfolio page lists DayOne as a February 2026 Anchor Fund technology investment.
On March 31, 2025, 65 Equity Partners backed the planned combination of HAS Healthcare Advanced Synthesis and Cerbios-Pharma and became an approximately 40% shareholder alongside the Braglia family. The official portfolio page also states that the firm partnered with Novo Tellus Capital Partners and TDConnex management in the acquisition of 100% of TDConnex.[4][5][6][7]
What is not clear from 65 Equity Partners's public investment criteria?
The official portfolio index lists fund strategy, sector, geography and month/year for investments but does not publish transaction consideration, ownership percentage or financing terms for the listed investments.
The official Theop announcement page identifies the announced partnership investment and its July 9, 2026 date but does not disclose transaction value, ownership percentage or financing terms. The official Anchor Fund 2 appointment release identifies Fullerton Fund Management and 65 Equity Partners as fund managers for the second S$1.5 billion tranche but does not state 65 Equity Partners’ individual committed capital, deployment target or investment terms.[5][8][9]
Questions to ask when evaluating 65 Equity Partners as a buyer or investment partner
Which legal entity and fund would make the investment?
Would the proposed transaction involve minority equity, co-controlling equity or structured equity?
What valuation range, preferred terms, governance rights and liquidity provisions would apply?
How much capital would be available for follow-on acquisitions and international expansion?
What is the expected ownership duration and exit approach for this specific investment?
Which Temasek or affiliated-fund resources would be available to the company?
What transaction fees, expenses, exclusivity terms, indemnities and management-retention expectations would apply?
Sources & research notes
- Official website / firm overview
- Structure / regulatory context
- Services / capabilities
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Public disclosure information
- Public disclosure information
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.